Yes. ALS is unfortunately not an attractive candidate to large pharmaceutical companies because the number of individuals with ALS is rather small. Technically speaking, by the international definition, ALS is considered to be a rare disease. So a biotech company looks for a compound that will be marketed to a large group of people, or to a group of people who will live and take the compound for 20 to 40 years. That makes a good market.
ALS is not a good market. We try to convince biotech companies that one benefit is the tremendous publicity they would get for any compound they came up with that was of benefit. That's something you can't buy. We all know the consequences to the biotech companies of negative publicity.
The fact of the matter is it's very hard to attract a biotech company to invest in the development of drugs for some of the neurological disorders.